About Civitas Therapeutics
Civitas Therapeutics is a company based in Chelsea (United States) founded in 2009 was acquired by Acorda in September 2014.. Civitas Therapeutics has raised $127.81 million across 5 funding rounds from investors including Acorda, Alkermes and Orbimed. Civitas Therapeutics operates in a competitive market with competitors including Harmony Biosciences, Avidity Biosciences, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter Chelsea, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Civitas Therapeutics Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Civitas Therapeutics
Civitas Therapeutics has successfully raised a total of $127.81M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $55.25 million completed in August 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $55.2M
-
First Round
First Round
(10 Jan 2011)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2014 | Amount | Series C - Civitas Therapeutics | Valuation | Orbimed , Rock Springs Capital | |
| Sep, 2013 | Amount | Series B - Civitas Therapeutics | Valuation | Bay City Capital | |
| Jun, 2013 | Amount | Grant - Civitas Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Civitas Therapeutics
Civitas Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Acorda, Alkermes and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Civitas Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Civitas Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Civitas Therapeutics Comparisons
Competitors of Civitas Therapeutics
Civitas Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harmony Biosciences, Avidity Biosciences, Univercells, Sutro Biopharma and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics for rare neurological diseases
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Civitas Therapeutics
Frequently Asked Questions about Civitas Therapeutics
When was Civitas Therapeutics founded?
Civitas Therapeutics was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Where is Civitas Therapeutics located?
Civitas Therapeutics is headquartered in Chelsea, United States. It is registered at Chelsea, Massachusetts, United States.
Is Civitas Therapeutics a funded company?
Civitas Therapeutics is a funded company, having raised a total of $127.81M across 5 funding rounds to date. The company's 1st funding round was a Grant of $1M, raised on Jan 10, 2011.
What does Civitas Therapeutics do?
Founded in 2009 and based in Chelsea, United States, Civitas Therapeutics operates as a biopharmaceutical company. A pipeline of inhaled therapeutics is developed using the ARCUS dry powder pulmonary delivery platform. The lead program, CVT-301, targets adjunctive therapy for Parkinsons disease patients experiencing OFF episodes. This involves a dry powder L-dopa formulation delivered via a reusable inhaler alongside oral regimens.
Who are the top competitors of Civitas Therapeutics?
Civitas Therapeutics's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Who are Civitas Therapeutics's investors?
Civitas Therapeutics has 14 investors. Key investors include Acorda, Alkermes, Orbimed, RA Capital, and Canaan.